APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuraminidase Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026182 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitors Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitors Drug Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitors Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitors Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitors Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuraminidase Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuraminidase Inhibitors Drug include Teva, Roche, Pfizer, GSK, AstraZeneca, Sun Pharmaceutical, Gilead Sciences, Daiichi Sankyo and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neuraminidase Inhibitors Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuraminidase Inhibitors Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuraminidase Inhibitors Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neuraminidase Inhibitors Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuraminidase Inhibitors Drug Segment by Company

Teva

Roche

Pfizer

GSK

AstraZeneca

Sun Pharmaceutical

Gilead Sciences

Daiichi Sankyo

Bristol-Myers Squibb

Neuraminidase Inhibitors Drug Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitors Drug Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Neuraminidase Inhibitors Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neuraminidase Inhibitors Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuraminidase Inhibitors Drug industry.

Chapter 3: Detailed analysis of Neuraminidase Inhibitors Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuraminidase Inhibitors Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Oseltamivir Table 3. Key Players of Laninamivir Table 4. Key Players of Peramivir Table 3. Key Players of Zanamivir Table 4. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Pharmacy Table 6. Key Players of Online Pharmacy Table 7. Key Players of Retail Pharmacy Table 8. Key Players of Others Table 9. Global Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2021-2026) Table 12. Global Neuraminidase Inhibitors Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Neuraminidase Inhibitors Drug Market Share by Region (2027-2032) Table 14. Neuraminidase Inhibitors Drug Industry Trends Table 15. Neuraminidase Inhibitors Drug Industry Drivers Table 16. Neuraminidase Inhibitors Drug Industry Opportunities and Challenges Table 17. Neuraminidase Inhibitors Drug Industry Restraints Table 18. Global Neuraminidase Inhibitors Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Neuraminidase Inhibitors Drug Revenue Market Share by Company (2021-2026) Table 20. Global Neuraminidase Inhibitors Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Neuraminidase Inhibitors Drug Key Company Head Office and Area Served Table 22. Global Neuraminidase Inhibitors Drug Company, Product Type & Application Table 23. Global Neuraminidase Inhibitors Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Neuraminidase Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Neuraminidase Inhibitors Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2021-2026) Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2027-2032) Table 31. Global Neuraminidase Inhibitors Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021-2026) Table 35. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2027-2032) Table 36. Teva Company Information Table 37. Teva Business Overview Table 38. Teva Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Neuraminidase Inhibitors Drug Product Portfolio Table 40. Teva Recent Development Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche Neuraminidase Inhibitors Drug Product Portfolio Table 45. Roche Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Neuraminidase Inhibitors Drug Product Portfolio Table 50. Pfizer Recent Development Table 51. GSK Company Information Table 52. GSK Business Overview Table 53. GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. GSK Neuraminidase Inhibitors Drug Product Portfolio Table 55. GSK Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Sun Pharmaceutical Company Information Table 62. Sun Pharmaceutical Business Overview Table 63. Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio Table 65. Sun Pharmaceutical Recent Development Table 66. Gilead Sciences Company Information Table 67. Gilead Sciences Business Overview Table 68. Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio Table 70. Gilead Sciences Recent Development Table 71. Daiichi Sankyo Company Information Table 72. Daiichi Sankyo Business Overview Table 73. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio Table 75. Daiichi Sankyo Recent Development Table 76. Bristol-Myers Squibb Company Information Table 77. Bristol-Myers Squibb Business Overview Table 78. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio Table 80. Bristol-Myers Squibb Recent Development Table 81. North America Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 82. North America Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 83. North America Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 84. North America Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 85. North America Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. North America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) Table 87. North America Neuraminidase Inhibitors Drug Market Size by Country (2027-2032) Table 88. Europe Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 89. Europe Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 90. Europe Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 91. Europe Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 92. Europe Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Europe Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) Table 94. Europe Neuraminidase Inhibitors Drug Market Size by Country (2027-2032) Table 95. China Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 96. China Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 97. China Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 98. China Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 99. Asia Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 100. Asia Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 101. Asia Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 102. Asia Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 103. Asia Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Asia Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) Table 105. Asia Neuraminidase Inhibitors Drug Market Size by Country (2027-2032) Table 106. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2021-2026) & (US$ Million) Table 107. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2027-2032) & (US$ Million) Table 108. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2021-2026) & (US$ Million) Table 109. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2027-2032) & (US$ Million) Table 110. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021-2026) Table 112. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitors Drug Product Image Figure 2. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neuraminidase Inhibitors Drug Market Share by Type: 2025 VS 2032 Figure 4. Oseltamivir Image Figure 5. Laninamivir Image Figure 6. Peramivir Image Figure 7. Zanamivir Image Figure 8. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Neuraminidase Inhibitors Drug Market Share by Application: 2025 VS 2032 Figure 10. Hospital Pharmacy Image Figure 11. Online Pharmacy Image Figure 12. Retail Pharmacy Image Figure 13. Others Image Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Neuraminidase Inhibitors Drug Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Neuraminidase Inhibitors Drug Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Neuraminidase Inhibitors Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2021-2032) Figure 23. Global Neuraminidase Inhibitors Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 26. North America Neuraminidase Inhibitors Drug Market Share by Type (2021-2032) Figure 27. North America Neuraminidase Inhibitors Drug Market Share by Application (2021-2032) Figure 28. North America Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 29. United States Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 30. Canada Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 33. Europe Neuraminidase Inhibitors Drug Market Share by Type (2021-2032) Figure 34. Europe Neuraminidase Inhibitors Drug Market Share by Application (2021-2032) Figure 35. Europe Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 36. Germany Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 37. France Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 39. Italy Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 40. Russia Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 42. China Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 43. China Neuraminidase Inhibitors Drug Market Share by Type (2021-2032) Figure 44. China Neuraminidase Inhibitors Drug Market Share by Application (2021-2032) Figure 45. Asia Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 46. Asia Neuraminidase Inhibitors Drug Market Share by Type (2021-2032) Figure 47. Asia Neuraminidase Inhibitors Drug Market Share by Application (2021-2032) Figure 48. Asia Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 49. Japan Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 53. India Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 54. Australia Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2021-2032) Figure 59. Brazil Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 64. UAE Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 66. Chile Neuraminidase Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Teva
  • Roche
  • Pfizer
  • GSK
  • AstraZeneca
  • Sun Pharmaceutical
  • Gilead Sciences
  • Daiichi Sankyo
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Oseltamivir
  5. 1.2.3 Laninamivir
  6. 1.2.4 Peramivir
  7. 1.2.5 Zanamivir
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacy
  11. 1.3.3 Online Pharmacy
  12. 1.3.4 Retail Pharmacy
  13. 1.3.5 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Neuraminidase Inhibitors Drug Growth Trends by Region
  16. 1.5.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Neuraminidase Inhibitors Drug Market Size by Region (2021-2026)
  18. 1.5.3 Neuraminidase Inhibitors Drug Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Neuraminidase Inhibitors Drug Market Dynamics
  1. 2.1 Neuraminidase Inhibitors Drug Industry Trends
  2. 2.2 Neuraminidase Inhibitors Drug Industry Drivers
  3. 2.3 Neuraminidase Inhibitors Drug Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitors Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neuraminidase Inhibitors Drug Revenue by Company (2021-2026)
  2. 3.2 Global Neuraminidase Inhibitors Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neuraminidase Inhibitors Drug Key Company Head office and Area Served
  4. 3.4 Global Neuraminidase Inhibitors Drug Company, Product Type & Application
  5. 3.5 Global Neuraminidase Inhibitors Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neuraminidase Inhibitors Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neuraminidase Inhibitors Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neuraminidase Inhibitors Drug Tier 1, Tier 2, and Tier 3
4 Neuraminidase Inhibitors Drug Market by Type
  1. 4.1 Global Neuraminidase Inhibitors Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neuraminidase Inhibitors Drug Market Size by Type (2021-2032)
  3. 4.3 Global Neuraminidase Inhibitors Drug Market Size Share by Type (2021-2032)
5 Neuraminidase Inhibitors Drug Market by Application
  1. 5.1 Global Neuraminidase Inhibitors Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuraminidase Inhibitors Drug Market Size by Application (2021-2032)
  3. 5.3 Global Neuraminidase Inhibitors Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Neuraminidase Inhibitors Drug Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Roche Neuraminidase Inhibitors Drug Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Neuraminidase Inhibitors Drug Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 GSK Neuraminidase Inhibitors Drug Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Sun Pharmaceutical
  32. 6.6.1 Sun Pharmaceutical Company Information
  33. 6.6.2 Sun Pharmaceutical Business Overview
  34. 6.6.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
  36. 6.6.5 Sun Pharmaceutical Recent Developments
  37. 6.7 Gilead Sciences
  38. 6.7.1 Gilead Sciences Company Information
  39. 6.7.2 Gilead Sciences Business Overview
  40. 6.7.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
  42. 6.7.5 Gilead Sciences Recent Developments
  43. 6.8 Daiichi Sankyo
  44. 6.8.1 Daiichi Sankyo Company Information
  45. 6.8.2 Daiichi Sankyo Business Overview
  46. 6.8.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
  48. 6.8.5 Daiichi Sankyo Recent Developments
  49. 6.9 Bristol-Myers Squibb
  50. 6.9.1 Bristol-Myers Squibb Company Information
  51. 6.9.2 Bristol-Myers Squibb Business Overview
  52. 6.9.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Recent Developments
7 North America
  1. 7.1 North America Neuraminidase Inhibitors Drug Market Size (2021-2032)
  2. 7.2 North America Neuraminidase Inhibitors Drug Market Size by Type
  3. 7.2.1 North America Neuraminidase Inhibitors Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Neuraminidase Inhibitors Drug Market Share by Type (2021-2032)
  6. 7.3 North America Neuraminidase Inhibitors Drug Market Size by Application
  7. 7.3.1 North America Neuraminidase Inhibitors Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Neuraminidase Inhibitors Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Neuraminidase Inhibitors Drug Market Share by Application (2021-2032)
  10. 7.4 North America Neuraminidase Inhibitors Drug Market Size by Country
  11. 7.4.1 North America Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Neuraminidase Inhibitors Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neuraminidase Inhibitors Drug Market Size (2021-2032)
  2. 8.2 Europe Neuraminidase Inhibitors Drug Market Size by Type
  3. 8.2.1 Europe Neuraminidase Inhibitors Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neuraminidase Inhibitors Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Neuraminidase Inhibitors Drug Market Size by Application
  7. 8.3.1 Europe Neuraminidase Inhibitors Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neuraminidase Inhibitors Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neuraminidase Inhibitors Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Neuraminidase Inhibitors Drug Market Size by Country
  11. 8.4.1 Europe Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neuraminidase Inhibitors Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neuraminidase Inhibitors Drug Market Size (2021-2032)
  2. 9.2 China Neuraminidase Inhibitors Drug Market Size by Type
  3. 9.2.1 China Neuraminidase Inhibitors Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Neuraminidase Inhibitors Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Neuraminidase Inhibitors Drug Market Share by Type (2021-2032)
  6. 9.3 China Neuraminidase Inhibitors Drug Market Size by Application
  7. 9.3.1 China Neuraminidase Inhibitors Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Neuraminidase Inhibitors Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Neuraminidase Inhibitors Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neuraminidase Inhibitors Drug Market Size (2021-2032)
  2. 10.2 Asia Neuraminidase Inhibitors Drug Market Size by Type
  3. 10.2.1 Asia Neuraminidase Inhibitors Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neuraminidase Inhibitors Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neuraminidase Inhibitors Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Neuraminidase Inhibitors Drug Market Size by Application
  7. 10.3.1 Asia Neuraminidase Inhibitors Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neuraminidase Inhibitors Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neuraminidase Inhibitors Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Neuraminidase Inhibitors Drug Market Size by Country
  11. 10.4.1 Asia Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neuraminidase Inhibitors Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst